Dr.Reddy’s Laboratories (NYSE:RDY) was upgraded by investment analysts at TheStreet from a “c” rating to a “b-” rating in a research note issued to investors on Thursday, TheStreetRatingsTable reports.
RDY has been the topic of several other research reports. Zacks Investment Research upgraded Dr.Reddy’s Laboratories from a “strong sell” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Friday, July 19th. ValuEngine downgraded Dr.Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Macquarie upgraded Dr.Reddy’s Laboratories from a “neutral” rating to an “outperform” rating in a research note on Monday, July 1st. Barclays started coverage on Dr.Reddy’s Laboratories in a research note on Tuesday, June 11th. They set an “equal weight” rating and a $39.00 target price on the stock. Finally, Morgan Stanley downgraded Dr.Reddy’s Laboratories from an “overweight” rating to an “equal weight” rating in a research note on Monday, May 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. Dr.Reddy’s Laboratories has an average rating of “Hold” and a consensus price target of $39.50.
Dr.Reddy’s Laboratories stock opened at $35.24 on Thursday. The company has a quick ratio of 1.32, a current ratio of 1.89 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $5.78 billion, a P/E ratio of 21.49 and a beta of 0.21. The stock’s 50 day moving average is $37.24 and its 200 day moving average is $38.50. Dr.Reddy’s Laboratories has a twelve month low of $31.58 and a twelve month high of $42.82.
Dr.Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Monday, July 29th. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.18. The company had revenue of $558.00 million for the quarter. Dr.Reddy’s Laboratories had a return on equity of 14.94% and a net margin of 13.44%. As a group, equities analysts expect that Dr.Reddy’s Laboratories will post 2.06 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Cornerstone Advisors Inc. raised its holdings in Dr.Reddy’s Laboratories by 93.3% in the 1st quarter. Cornerstone Advisors Inc. now owns 949 shares of the company’s stock worth $38,000 after purchasing an additional 458 shares during the period. Parallel Advisors LLC raised its holdings in Dr.Reddy’s Laboratories by 172.1% during the first quarter. Parallel Advisors LLC now owns 1,045 shares of the company’s stock valued at $42,000 after acquiring an additional 661 shares during the period. Private Capital Group LLC raised its holdings in Dr.Reddy’s Laboratories by 58.2% during the first quarter. Private Capital Group LLC now owns 1,169 shares of the company’s stock valued at $47,000 after acquiring an additional 430 shares during the period. Advisors Preferred LLC bought a new stake in Dr.Reddy’s Laboratories during the second quarter valued at about $55,000. Finally, NumerixS Investment Technologies Inc raised its holdings in Dr.Reddy’s Laboratories by 120.0% during the second quarter. NumerixS Investment Technologies Inc now owns 2,200 shares of the company’s stock valued at $82,000 after acquiring an additional 1,200 shares during the period. 12.82% of the stock is currently owned by institutional investors.
About Dr.Reddy’s Laboratories
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.
See Also: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.